Identification of an acquired JAK2 mutation in polycythemia vera. - Wikidata - awgldk - TriplyDB

Identification of an acquired JAK2 mutation in polycythemia vera.

Identification of an acquired JAK2 mutation in polycythemia vera.

http://www.wikidata.org/entity/Q33947635

about

Conditional deletion of Jak2 reveals an essential role in hematopoiesis throughout mouse ontogeny: implications for Jak2 inhibition in humans Phosphorylation of p27Kip1 by JAK2 directly links cytokine receptor signaling to cell cycle control Janus kinases in immune cell signaling The molecular mechanisms that control thrombopoiesis JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies Therapeutic targeting of Janus kinases Erythropoietin stimulates phosphorylation and activation of GATA-1 via the PI3-kinase/AKT signaling pathway Erlotinib effectively inhibits JAK2V617F activity and polycythemia vera cell growth Potential Role of JAK-STAT Signaling Pathway in the Neurogenic-to-Gliogenic Shift in Down Syndrome Brain Targeting JAK2 in the therapy of myeloproliferative neoplasms The azaindole framework in the design of kinase inhibitors Signal transduction in the chronic leukemias: implications for targeted therapies Janus kinase inhibitors: jackpot or potluck?The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms The treatment of polycythaemia vera: an update in the JAK2 era An unconventional antigen translated by a novel internal ribosome entry site elicits antitumor humoral immune reactions Efficacy of NS-018, a potent and selective JAK2/Src inhibitor, in primary cells and mouse models of myeloproliferative neoplasms Quantitative histological image analyses of reticulin fibers in a myelofibrotic mouse Receptor specific downregulation of cytokine signaling by autophosphorylation in the FERM domain of Jak2 Differential biological activity of disease-associated JAK2 mutants Efficacious intermittent dosing of a novel JAK2 inhibitor in mouse models of polycythemia vera Multifaceted intervention by the Hsp90 inhibitor ganetespib (STA-9090) in cancer cells with activated JAK/STAT signaling Mouse models of myeloproliferative neoplasms: JAK of all grades Splenectomy normalizes hematocrit in murine polycythemia vera JAK2 (V617F) Positive Latent Myeloproliferative Neoplasm Presenting with Splanchnic Vein Thrombosis A data-driven network model of primary myelofibrosis: transcriptional and post-transcriptional alterations in CD34+ cells.Novel tumor antigens elicit anti-tumor humoral immune reactions in a subset of patients with polycythemia vera JAK2 V617F in myeloid disorders: what do we know now, and where are we headed?Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis.Therapy with the histone deacetylase inhibitor pracinostat for patients with myelofibrosis Biology and clinical management of myeloproliferative neoplasms and development of the JAK inhibitor ruxolitinib Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies Structural effects of clinically observed mutations in JAK2 exons 13-15: comparison with V617F and exon 12 mutations.Design and evaluation of a real-time PCR assay for quantification of JAK2 V617F and wild-type JAK2 transcript levels in the clinical laboratory Human-induced pluripotent stem cells from blood cells of healthy donors and patients with acquired blood disorders Jak2 inhibitors: rationale and role as therapeutic agents in hematologic malignancies.AKT is a therapeutic target in myeloproliferative neoplasms Transforming JAK1 mutations exhibit differential signalling, FERM domain requirements and growth responses to interferon-γ.

P2860

Q21133609-4060CDF5-BFD1-444A-871E-88E6084F1E84 Q24297854-56D8D371-A3A4-4247-94DE-87B338A69D94 Q24322021-6FBA72E7-4788-4224-B647-A86A00094A48 Q24536138-0916E315-17CE-436A-92DB-A7D2E1F16256 Q24609999-00B489CA-4610-4BFC-9617-E35E70512367 Q24648438-B7643C44-C4FF-48DA-8EA7-CC7F867BAF64 Q24658483-8139AA22-A1C7-4577-85BE-A235E8052ACE Q24685447-3D18C5C6-0387-42C4-AD88-D73BCD7CE5E3 Q24685474-7A549636-9758-447B-9D25-2C5FE8EC52A8 Q26765647-0121770A-8ACB-4C9E-B9B9-BE2A66ED1B58 Q26860796-1E4FFC3D-2429-485E-8FEF-97819D142AAD Q27013668-5A64862B-BD01-48DD-838C-DD126EB1C1AF Q27026031-F6E7B93B-4F1D-4FFB-8255-202CE62D1F3D Q27027230-0B9D38F2-562A-4A53-9778-248CF50BE77B Q27266125-BDB17BDA-20A5-4FAB-B94D-865BA5910120 Q27851467-966B1C9F-E6E0-4610-A87C-869B659B41E6 Q28212560-CB7A09ED-74F4-4617-81CD-DB021F7A4F94 Q28264336-5422293F-DF26-49DB-918A-74DF0F184AE7 Q28271752-6BC517AC-6B4F-4713-94C4-4355791EA33A Q28364884-766856DB-DF96-4DFF-B328-AA68953902F6 Q28506187-319CA7A4-97BD-40C3-B217-F79E4F880170 Q28508045-131FF182-2CE3-40B9-9B79-B81565A2E984 Q28729862-B77CAEAC-16FD-4C90-9351-06ADDBCBB986 Q28741023-A09D9914-557E-48C0-BA79-21C505B668E3 Q28744478-C3730CF6-3FF0-4065-BC0E-5F98206FA321 Q28751387-1E1389A5-2CE4-4813-B607-BA76E5312D2B Q30303071-EB95986F-BE2E-44AF-B4E0-640D915F1941 Q31110460-1CF2565D-EFCD-453A-90F0-D6F180EE5A2A Q33264010-D7792DC7-DFDC-4D2A-A9D9-F0A33123B22B Q33341856-0C860D95-1F03-4169-BAC4-14AB8D03A743 Q33386057-E0F5A50D-4450-4D8E-8B9B-B4EF99257077 Q33400570-4334DCE2-4E39-495D-AEC4-A37026F8B200 Q33402522-A20D9C4F-0BF5-4D3C-983E-FD3F65D20EAE Q33437478-7FDD4258-6E78-42EE-B093-820614AE5937 Q33501856-23A298AC-0532-4610-8066-0B724B3DBCCC Q33555643-1D7BA2D9-CC61-4BA2-AB7E-22B0C5259191 Q33560423-036FDBE8-F9E9-48A1-A261-165063600CAC Q33586552-F2894A42-40B6-4BA6-B1BE-751315E180DA Q33623277-8D9D337E-3F47-4A98-A9BA-EF091025E032 Q33702627-1A8CD451-E082-48B1-A504-B6DE82CB52F0

P2860

Identification of an acquired JAK2 mutation in polycythemia vera.

http://www.wikidata.org/entity/Q33947635

description

2005 nî lūn-bûn

@nan

2005 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Identification of an acquired JAK2 mutation in polycythemia vera.

@ast

Identification of an acquired JAK2 mutation in polycythemia vera.

@en

type

label

Identification of an acquired JAK2 mutation in polycythemia vera.

@ast

Identification of an acquired JAK2 mutation in polycythemia vera.

@en

prefLabel

Identification of an acquired JAK2 mutation in polycythemia vera.

@ast

Identification of an acquired JAK2 mutation in polycythemia vera.

@en

P1433

Q33947635-881D8756-00FD-4EC5-87E1-35FFE0D26594

P1476

Q33947635-ED11CDF9-AA8A-4A07-A1D7-4B654DBA77B7

P2093

Q33947635-17D5AC25-CAAE-4D6C-8371-DB80E4D3549F

Q33947635-1B312387-29DF-4C74-AE19-3AA3F0518CC8

Q33947635-57F6DFF0-9F8B-40BE-8FED-73199A957BFC

Q33947635-9A120F55-7B39-499A-AFC0-195D434F6784

Q33947635-C6195F03-D6BB-49AC-AB1F-C170DD0CB513

Q33947635-D08209A6-A935-43D6-BBE5-A027D701BCAE

P2860

Q33947635-178C745B-BBD2-453C-AA80-9ADFABA82F4B

Q33947635-28351704-FDA3-4AE1-BAA7-0BFCBC677CCD

Q33947635-2909317A-A69E-46EF-BF57-90C765049B39

Q33947635-2D547970-3094-443A-8614-A61400A46341

Q33947635-2E64A34E-BBF2-4D3C-AB5C-A3E77E8BB4FE

Q33947635-35E2EC1F-C1E3-4793-8BD1-C9FFD99780CC

Q33947635-3C21591A-4B51-48A1-AFDF-61E000585EA4

Q33947635-3CC4E51A-4C32-4A54-80AB-A28148718781

Q33947635-3F859F45-0A7F-411D-814B-0A1CB801AC92

Q33947635-4157EBDC-33EC-4C10-BCF7-22FB052E957C

P304

Q33947635-84F81A96-658F-4711-A674-AFA533B65B5D

P31

Q33947635-B378C8A8-7E37-430E-94B5-B49063C56487

P356

Q33947635-ABAF4BD6-1F6C-42E2-8F4D-7BDFD1A8A5E7

P407

Q33947635-B027E1BC-6D96-4213-AC6B-B126F8FCD5AC

P433

Q33947635-DA2205EF-8038-4981-A256-3DF71531EDED

P478

Q33947635-9D628902-B1F5-439E-BE44-C451CE2CA3F6

P50

Q33947635-4D8278E0-A339-454C-9346-B3F58A6A7516

P577

Q33947635-D76AAB0C-26CC-462D-9E78-570A81206F12

P5875

Q33947635-B9C0284E-E59D-4DE3-B152-A58B43A744F9

P698

Q33947635-9884FA54-9F9F-4545-9D27-D5957F94670B

P932

Q33947635-C8990D6C-7431-4549-B778-19B0091F1F0A

P356

P1433

Journal of Biological Chemistry

P1476

Identification of an acquired JAK2 mutation in polycythemia vera.

@en

P2093

Qingshan Li

http://www.w3.org/2001/XMLSchema#string

Runxiang Zhao

http://www.w3.org/2001/XMLSchema#string

Sanford B Krantz

http://www.w3.org/2001/XMLSchema#string

Xueqi Fu

http://www.w3.org/2001/XMLSchema#string

Zhe Li

http://www.w3.org/2001/XMLSchema#string

Zhizhuang Joe Zhao

http://www.w3.org/2001/XMLSchema#string

P2860

Genomic analysis of the eukaryotic protein kinase superfamily: a perspective

Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis

The protein kinase complement of the human genome

Janus kinases and focal adhesion kinases play in the 4.1 band: a superfamily of band 4.1 domains important for cell structure and signal transduction

Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins

Protein kinases 6. The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification

The Jak-Stat pathway in normal and perturbed hematopoiesis

Signaling through the JAK/STAT pathway, recent advances and future challenges

Mutational analysis of the tyrosine kinome in colorectal cancers

Protein tyrosine phosphatases in the human genome

P304

22788-22792

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1074/JBC.C500138200

http://www.w3.org/2001/XMLSchema#string

P407

P433

24

http://www.w3.org/2001/XMLSchema#string

P478

280

http://www.w3.org/2001/XMLSchema#string

P50

P577

2005-04-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7873700

http://www.w3.org/2001/XMLSchema#string

P698

15863514

http://www.w3.org/2001/XMLSchema#string

P932

1201515

http://www.w3.org/2001/XMLSchema#string